Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merakris Receives FDA Clearance For Phase II Dermacyte® Liquid Study
Details : Dermacyte (human amniotic fluid), a cell-free amniotic injection, that is being developed in Phase 2 clinical trial for the treatment of venous stasis ulcer.
Brand Name : Dermacyte
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 05, 2024
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
Details : Dermacyte (human amniotic fluid), a cell-free amniotic injection, that is being developed in Phase 2 clinical trial for the treatment of venous stasis ulcer.
Brand Name : Dermacyte
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dermacyte® Amniotic Wound Care Liquid (human amniotic fluid), a cell-free amniotic injection that is being developed under Merakris’ investigational New Drug (IND) approval for would healing.
Brand Name : Dermacyte Liquid
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 29, 2022
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : US Department of Veterans Affairs
Deal Size : Undisclosed
Deal Type : Agreement
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
Details : Merakris has entered into a Cooperative Research and Development Agreement with the VA and is currently negotiating with additional clinical sites to conduct the two-part Phase II clinical trial for Dermacyte, Human Amniotic Fluid.
Brand Name : Dermacyte
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 27, 2022
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : US Department of Veterans Affairs
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Study Shows Effectiveness of Merakris Wound Care Products
Details : A single combination treatment with Dermacyte Liquid and Dermacyte Matrix (Human Amniotic Fluid) healed smaller of two wounds in four weeks. Dermacyte Liquid was injected under skin around wounds on patient’s thigh and lower leg.
Brand Name : Dermacyte Liquid
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 02, 2022
Lead Product(s) : Human Amniotic Fluid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?